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reduced and drug molecules can be transfected into different cells
via endocytosis. This is in contrast to microparticles, which tend
to be taken up only by large cells (e.g., macrophages) or remain
outside the target cells. Several different nanomaterials such as
layered double hydroxides (LDH),1 liposomes2 and polymeric
nanoparticles3 have been considered as delivery vehicles for the
controlled and targeted release of biomolecules. Mesoporous
silica nanoparticles (MSNs) form another important group of
inorganic delivery systems. They are ideal candidates due to their
controllable morphologies, mesostructures and porosities, and
their high level of biocompatibility and ease of functionalisation.
Since the discovery of the MCM-41s family in 1992, the
synthesis of new mesoporous silica materials has advanced
rapidly.4 The most well known and common families of MSNs
include MCM-n,4 SBA-n (Santa Barbara amorphous silica),5
MSU-n (Michigan State University silica),6 KIT-1 (Korean
Institute of Technology),7 IBN (Institute of Bioengineering and
Nanotechnology)8 and FDU-n (Fudan University).9 Each family
has its own unique advantages and disadvantages, and all have
been successfully utilised in various applications. These appli-
cations include drug delivery, catalyst supports, adsorption and
separation of proteins, cell imaging, cell labelling, enzyme
adsorption and immobilisation. Additionally, mesoporous silica
materials can be synthesised together with other nanomaterials
to create new nanocomposites, opening up a wide variety of
potential applications. The ready functionalisation of silica
materials makes them ideal candidates for bioapplications and
catalysis. Furthermore, as porous structures, they exhibit high
surface areas, large pore volumes and ordered pore networks.
These properties of mesoporous silica allow higher loading of
drugs or biomolecules, improved control over the loading and
release kinetics, and higher biocompatibility since it is easy for
them to be chemically modified.
There have been many excellent reviews regarding synthesis of
mesoporous silica and their applications in the past few years.10–17
However, with the exponential growth of research in meso-
porous silicas over the last five years, it is important to provide
a concise and critical review of the latest advances. This review
will focus on a few prominent topics such as protein adsorption,
drug delivery, DNA/siRNA/vaccine delivery and enzyme
immobilisation, including the usage of composite magnetic silica
materials as an enzyme nanocarrier. We summarise some of the
most significant advances in the field of MSNs for biomedical
applications and enzyme immobilisation in Tables 1 and 2,
respectively. This review will give an insight into the different
types of biomolecules that can be delivered using MSNs and the
key factors affecting encapsulation or adsorption of those
biomolecules and their release mechanisms. Furthermore,
important aspects of cytotoxicity of MSN materials will be
discussed.2. Mesoporous silica nanoparticles
2.1 Introduction to MSNs
For many biomedical applications, an ideal delivery system
should be able to deliver a chemical or biomolecule to a targeted
site in a controlled manner. The prerequisites for ideal controlled
delivery systems are: (1) biocompatibility and biodegradability,2802 | Nanoscale, 2011, 3, 2801–2818(2) controlled release of cargo, (3) controlled loading and tar-
geted release of therapeutics, (4) zero premature release and (5)
stimuli responsiveness. It is difficult to find an ideal material for
a delivery system with all these properties and functionalities. To
this end, various delivery systems have been designed and
developed. Polymeric nanoparticles, dendrimers, and liposomes
were tested as smart materials to achieve an ideal controlled
delivery system.18–20 Several drug delivery systems have been
tested for zero premature release, but in most cases the cargo
molecules entrapped in matrices of polymers or inorganic
particles would leak out within a few hours due to diffusion or
degradation of the polymer matrix. In order to overcome this
leaking issue, several nanoparticle-based systems have been
recently investigated, including mesoporous silica nanoparticles
(MSNs).21
Many articles have been published on the synthesis of MCM-
41 type of materials since Mobil’s discovery. However Cai et al.
first reported factors affecting morphology control and particle
size of MCM-41 type of MSN.22 They synthesised nanospheres
(110 nm), sub-micrometre sized rods and micron sized oblates
with strong stirring at extremely low surfactant concentration
and basic pH conditions. Furthermore, they proposed a detailed
mechanism of the formation of mesoporous silica nanoparticles
with different shapes and sizes. They concluded that the synthesis
of MCM-41 type of materials involves nucleation and self
assembly of silica precursor under alkaline conditions in the
presence of a template. The morphology of the particle is then
determined by the type of catalyst used, for example, NH4OH
leads to a rod-like morphology, while NaOH forms short and
smaller size micelles, making the particles spherical.
To date many drugs have been studied for adsorption and
release in MSNs (Table 1). However, due to the small pore sizes
of the MCM-type materials, the molecule size that could be
incorporated and loaded inside the pores was limited to 2–3 nm.
Therefore, larger molecules such as proteins, enzymes and DNA
could not be used. By changing the pH, temperature, and type of
surfactant, a variety of mesoporous materials have been
successfully synthesised with varying sizes, shape and
morphology. Recently, Nazar and co-workers23 reported
a strategy for the synthesis of SBA-15 type nanorods with a small
particle size (300–600 nm in length) and large pores (6 nm)
using a very dilute solution of P123 in contrast to all other
reports based on SBA-15. They showed that due to a low
concentration of the template and mild acidic conditions, parti-
cles were smaller in size and of different morphology than earlier
reported.23 Kim et al.24 prepared for the first time SBA-15- type
nanospheres with a mean diameter of 500–600 nm using pluronic
P104 as a template and tetramethyl orthosilicate (TMOS) as
a silica precursor. This is particularly important as SBA-15 type
materials exhibit higher thermal and chemical stability than
MCM-41 type silicas.
Han et al. synthesised IBN-type mesoporous silica nano-
particles with a 3D cubic (Im3m) structure and large pore size by
using cationic fluorocarbon surfactants with a higher surface
activity and lipophobic nature.23 Using different surfactants as
templates and trimethylbenzene (TMB) as a pore swelling agent,
they synthesised particles with different pore sizes and meso-
structures (IBN-1 to IBN-5). They were able to enlarge the pore
size to 20 nm.This journal is ª The Royal Society of Chemistry 2011
Table 1 Different types of drugs loaded onto mesoporous silicas
Material Chemical moiety Modification Adsorption mechanism Release mechanism Ref
FSM Taxol Unmodified Diffusion through pore
size and type of solvent
Diffusion from different pore
size
40
MCM-41 Ibuprofen Different surfactants Impregnation Diffusion 80
MCM-41 Ibuprofen Unmodified Impregnation Diffusion from different pore
size
13
MCM-41 Ibuprofen -NH2 functionalisation Impregnation Diffusion 80
MCM-41 Vancomycin Thiol functionalisation and
cyclodextrin capped
Impregnation Upon addition of reducing
agents
61
MCM-41 Gentamycin PLGA/Silica hybrid
particles
Impregnation Diffusion through polymer
matrix
127
MCM-41 Antibacterial agents Room temperature ionic
liquid containing silica
Impregnation Shape and morphology driven
release
128
SBA-15 Gentamycin Unmodified Impregnation Diffusion 129
SBA-15 Amoxicillin Large pore ordered SBA-15 At different pH and
solvent
Depending on the physical
shape of the particles
130
MCM-48 Erythromycin Unmodified Impregnation Diffusion from Cubic structure 13
SBA-15 Erythromycin Hydrophobic group
attachment
Impregnation Release from the functionalised
surface via diffusion
63
MCM-41 Aspirin Different functionalisation
methods
Impregnation Diffusion: No noticeable
different
131
MCM-41 Ibuprofen Addition of different
hydrophobic groups by post
synthesis grafting
Simple impregnation Diffusion through pores and
surface functional groups
81
MCM-41 and SBA-15 Alendronate Amino functionalisation Simple impregnation Diffusion and dissolution First
order kinetics in case of SBA-15
67
MSN type II DNA into plant cells Triethylene glycol
functionalised
DNA was modified with
promoter in order to
attach it to MSN-II
Gate opening triggers have to
be used to open gate in order to
release DNA into cells
54
MCM-41 Camptothecin Amino and phosphonate
functionalised
Simple impregnation Diffusion 64
Hollow Mesoporous
silica nanoparticles
Fluorescein
isothiocyanate
Amino functionalised Simple impregnation Diffusion 132
SBA-15 L-tryptophan Unmodified Simple impregnation Diffusion 66
MCM-41 Atenolol Hydroxy apatite/Silica
composite
Simple impregnation Slow diffusion due to composite
(HA/MCM-41)
133
MCM-41 Ibuprofen Different particle
morphology and amine
functional groups
Simple impregnation Dependent on morphology and
functional group
37
SBA-15 Bovine serum albumin
(BSA)
Hydrogel encapsulated Loading after coating
at low pH
pH driven release 123
MCM-41 Cytochrome C Unmodified Diffusion/large pore Uptake by cell membrane 134
MCM-41 BSA PEGylated Simple impregnation Diffusion through hydrophilic
polymer
77
MCM-41 Paclitexel -NH2 Simple impregnation Energy dependent cellular
uptake
79
MCM-41 DNA/gene Monnosylated polyethylene
amine
Simple impregnation Receptor mediated release 135
SBA-15 Sodium alendronate -NH2 Simple impregnation Diffusion/degree of
functionalisation
72
MSN Orange-II Trimethylammonium
(Positively charged)
Simple impregnation pH controlled release 136
MSN Rhodamine-B a-CD Simple impregnation Enzyme responsive 60
MCM-41 Vitamine-B2 -NH2 Simple impregnation pH responsive 62
MSN with Ultra
large pore size
Protein separation Unmodified Due to large pores Molecular sieving 137
MCM-41 Calcein Coated with lipid bilayer Simple impregnation pH dependent release 138
MSN DNA Novel double surfactant
system
Diffusion/large pores NONE 47
Colloidal mesoporous
silica (CMS)
Biotin and Avidin Thiol functionalised Covalent bonding Enzyme responsive 139
MSN Ibuprofen Dual-template technique Simple impregnation Diffusion 140
MCM-41 Safranine O Attached with saccharide
coated gold nanoparticles
Simple impregnation Photo and pH responsive (Dual
mechanism)
122
MCM-41 Paclitacxel Capped with Au-Nps Simple impregnation Photo induced 86
MSN Alendronate Coating of hydroxy apatite
and PLGA
Simple impregnation Dissolution-diffusion
controlled
85
MCM-41 Ibuprofen Magnetic nanoparticles
containing silica were
coated with PLGA
Simple impregnation Dissolution-diffusion
controlled
141
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Table 1 (Contd. )
Material Chemical moiety Modification Adsorption mechanism Release mechanism Ref
MCM-41 Cyclic AMP Borinic acid functionalised Simple impregnation Glucose responsive 82
PMOs Tetracycline Morphology controlled Simple impregnation Diffusion 33
SBA-15 Nimodipine Unmodified Liquid phase grafting Diffusion 142
MNP (Mechanised
nanoparticles made
of MSNs)
Propidium Iodide Functionalised with
cucurbituril
Post synthesis grafting pH responsive release 84
Hollow MSNs Propidium Iodide a- CD & Organic linkers Post synthesis grafting pH responsive release 126
MNP Pyrin modified b- CD,
Rhodamine B
Azobanzene functionalised Co-condensation Light operated 143
MSNs Coumarin 540A Azobanzene functionalised Co-condensation Photo-driven 83Another very unique 3D cubic structured (Id3d)MCM-48 type
of MSNs has been synthesised by many researchers.25–28With the
advantage of an open network, it provides easy and direct access
to host molecules. However, the synthesis of these types ofMSNs
requires a time-consuming hydrothermal treatment. Moreover,
the large particle size of >1 mm makes them unattractive as drug
delivery carriers.25,26 Many researchers have tried to decrease the
particle size, while keeping monodisperse nanoparticles. Schu-
macher et al. have developed these types of particles at room
temperature with a particle size of <1 mm, but still it is not useful
for cell-based delivery of proteins and genes.27,28
Recently, Kim et al. published a very detailed and sophisti-
cated synthesis process of MCM-48 type spherical monodisperse
nanoparticles with a particle size between 50–70 nm, a pore size
of 2.3–3.3 nm and very high BET surface area of approximately
1250 m2 g1. Synthesis was carried out via the modified St€ober
method using pluronic F127 to control particle size and alkyl
chain surfactants for pore structure control. They investigated
the effect of stirring rate, CTAB concentration, and post thermal
treatment onto particle size, pore volume, surface area and pore
diameter. So far, this is the only article that reports on mono-
disperse MCM-48 type of MSNs.30 This could be very useful in
the field of drug delivery as high surface area, small particle size,
and an ordered and unique 3D structure make them ideal for the
adsorption of biomolecules. Comparison studies between
different types of mesoporous structures with controlled
morphology and their effects on adsorption and desorption of
biomolecules have not yet been conducted.
Another novel class of MSNs is the hollow mesoporous silica
nanosphere. Because of its low density, large surface area and
well-defined wall structure, they can be used in a variety of
applications including drug delivery. We first synthesised PMO
hollow spheres with tunable wall thickness using a novel dual
templating approach.31 Fluorocarbon and CTAB were used as
dual templates and 1,2-bis(trimethoxysilyl)ethane was used as
the hybrid silica precursor.
Later, the surface functionalised hollow nanospheres with
different terminal groups such as –SH, –NH2, –CN, –C]C, and
benzene were synthesised. Disruptive effects of different func-
tional groups on the structure of the hollow sphere was identified
for further functionalisation.32We then used these novel particles
for delivery of tetracycline. Adsorption of tetracycline was
increased by adding a vinyl group (as opposed to other func-
tional groups such as –SH, –NH2 and –CN
33) onto the surface of
the silica.2804 | Nanoscale, 2011, 3, 2801–2818Very recently, Liu et al.34 reported the synthesis of multi-
shelled hollow nanospheres with an average particle size of
150 nm (Fig. 1). Multi-shelled spheres can be effectively utilised
to adsorb different chemical molecules in each shell. Release of
each biomolecule can be tuned using different shell thickness.
Moreover, these particles showed very high affinity towards
Ibuprofen (448 mg g1) due to their low density and high surface
area. QDs (Quantum Dots) and Ibuprofen were successfully
loaded into shells. Release of Ibuprofen molecules was slow and
sustained.
In addition to the above-mentioned MSNs systems, many
groups are researching the preparation and characterisation of
novel core-shell particles.35,36 One such type of systems is yolk
shell nanoparticles with a porous shell and a functional core. We
synthesised mono-dispersed yolk shell nanoparticles with meso-
porous silica nanoparticles as a core and a mesoporous shell with
tunable thickness (Fig. 2).34 Interestingly, we observed a unique
three-step release process of Ibuprofen from the nanoparticles.2.2. Physicochemical parameters affecting adsorption and
release of biomolecules in MSNs
Table 1 summarises the drugs, genes, proteins and DNA that
have been used, loaded into, or attached to MSN materials.
There are four major factors that affect adsorption and release of
biomolecules in MSNs.
2.2.1 Particle size and morphology. Monzano et al. studied
the effect of particle size on the loading and release of Ibuprofen.
They used MCM-41 type particles with a particle size ranging
from 490–770nm. They concluded that controlled drug release
was achieved with smaller spherical particles. However, in
regards to irregular shaped micron-sized particles, drug release
was very slow. Additionally, they showed that spherical particles
are better candidates for controlled drug release than irregular
shaped ones.37 Qu et al. also showed the effect of MSN shape on
the adsorption of captopril. They concluded that adsorption of
captopril was higher in rod shaped particles than in spherical
particles.38 Later, Qiao and co-worker39 produced helical rod like
MSNs with a highly ordered structure. They published detailed
mechanisms for the synthesis of these types of 1D rod like
particles which showed controlled release of Aspirin.
2.2.2 Pore size. Pore size is one of the most important factors
affecting selective adsorption and release of host moleculesThis journal is ª The Royal Society of Chemistry 2011
Table 2 Summary of enzyme immobilisation on various mesoporous silica material
No
Mesoporous silica and
related pore size Enzymes Loading mg g1 Immobilized enzymes activity Year Ref
1 MCM 41 P6mm 40 A cytochrome c (bovine heart) (30 A) 3.8–5.8 1996 165
MCM 41 P6mm 40 A Papain (papaya latex) (36 A) 0.5–4.9 1996 165
MCM 41 P6mm 40 A trypsin (bovine pancreas) (38 A) 3.8–4.7 1996 165
MCM 41 P6mm 40 A Peroxidise (46 A) 0.4 1996 165
2 MCM 41 P6mm 33.2 A Penicillin Acylase (PA) 23% in weight The direct immobilization had
a higher activity compared to the
covalent coupling
2000 189
3 FSM-16 89 A Horseradish peroxidise (HRP) 183 2000 190
MCM 41 P6mm 66 A Horseradish peroxidise (HRP) 147 2000 190
SBA-15 92 A Horseradish peroxidise (HRP) 24 2000 190
4 MCM 41 P6mm 35 A Trypsin (bovine pancreas)(38 A) 90% of trypsin
were immobilized
2001 191
MCM 48 24 A Trypsin (bovine pancreas) (38 A) 2001 191
SBA 15 56 A Trypsin (bovine pancreas) (38 A) 2001 191
5 SBA 15 75 A A crude lipase (Newlase F) 50–300% higher than the crude
enzyme
2002 114
6 MCM 41 P6mm 36–41 A a-Chymotrypsin 40  40  50 A 170 Activation with trypsin had
a higher activity
2003 192
7 MCM 41 P6mm 45 A Trypsin 5 mmol g1 Immobilized trypsin had
comparable activity as a native
trypsin
2003 193
8 HMS 40.4 A Hemoglobin (Hb) (molecular
weight: 64,500)
Immobilised Hb retained its
activity and showed an excellence
performance as a biosensor
2004 194
9 HMS 40.4 A Myoglobin (Mb) ImmobilisedMb showed promising
properties for biosensor
2004 195
10 Amine functionalized
mesopore cellular foam
(AF-MCFs) 170–340 A
Glucose oxidase (Gox) (molecular
weight: 33,000)
210 High catalytic activity and thermal
stability
2005 78
11 MCM-41 47 A Candida Antarctica Lipase B 10 Enzyme immobilised within
methylated samples showed higher
activities
2008 196
SBA-15 88 A Candida Antarctica Lipase B 44 2008 196
Methylated SBA-15 79 A Candida Antarctica Lipase B 23 2008 196
KIT-6 84 A Candida Antarctica Lipase B 37 2008 196
Methylated KIT-6 77 A Candida Antarctica Lipase B 35 2008 196
SBA-16 102 A Candida Antarctica Lipase B 5 2008 196
Methylated SBA-16 88 A Candida Antarctica Lipase B 30 2008 196
FDU-12 104 A Candida Antarctica Lipase B 28 2008 196
Methylated FDU-12
97 A
Candida Antarctica Lipase B 37 2008 196
Amorphous mes. Silica
279 A
Candida Antarctica Lipase B 45 2008 196
12 KIT-6 67–72 A Penicilin G acylase (PGA) (70  50
 55 A)
Enzyme immobilised within larger
pore size support had higher
specific activities
2008 174
SBA-15 62–71 A Penicilin G acylase (PGA) (70  50
 55 A)
2008 174
13 SBA-15 67 A Porcine pepsin (molecular weight
34,000 and size 55  74  36 A)
117.4 High catalytic activity which
similar to the free enzyme
2008 197
14 APTES functionalized
SBA-15
Penicillin acylase 68 Retained 73% activity of its free
formed
2008 181
15 SBA-15 60.7 A Lysozyme 75a 2009 119
PMO: BTMS-amine
89.0 A
Lysozyme — 2009 119
PMO: BTES-benzene
42.2 A
Lysozyme 50a 2009 119
PMO: BTES-byphenyl
36.0 A
Lysozyme 75a 2009 119
16 Hydrophilic sphere silica Thermomyces lanuginose lipase 1.3 Specific activity is similar with the
free enzymes
2010 198
Hydrophobic sphere
silica
Thermomyces lanuginose lipase 0.77 Specific activity increases 2.5 times
compared to free enzymes
2010 198
17 FSM 16 27 A Lipase (Phycomyces nitens) 7.5b Much higher activity compared to
the free enzymes
2010 199
FSM 7 70 A Lipase (Phycomyces nitens) 13.0b 2010 199
18 FDU 12 Fm3m 280 A BSA (Bovine Serum Albumin) 36.14 2009 112
FDU 12 Fm3m 280 A Cellulase enzyme (Trichoderma
reesei)
10.35 2009 112
Amine-FDU12 Fm3m
254 A
BSA (Bovine Serum Albumin) 132.57 2009 112
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Table 2 (Contd. )
No
Mesoporous silica and
related pore size Enzymes Loading mg g1 Immobilized enzymes activity Year Ref
Amine-FDU12 Fm3m
254 A
Cellulase enzyme (Trichoderma
reesei)
21.80 2009 112
19 Functionalized-FDU 12c
Fm3m
BSA (Bovine Serum Albumin) 50.9d 2010 182
Functionalized-FDU 12c
Fm3m
Cellulase enzyme (Trichoderma
reesei)
18.19d Vinyl-FDU12 showed the highest
activity which retained 80% of the
free enzyme activity
2010 182
20 SBA-15 97.1 A Penicillin G acylase 89.8% The enzyme immobilised
withinVTES-SBA-15 had the
highest activity which is twice then
the free enzymes
2004 172
APTES-SBA 15 99.3 A Penicillin G acylase 95.9% 2004 172
Glutar-SBA 15 Penicillin G acylase 94.1% 2004 172
MPTMS-SBA 15 97.1 A Penicillin G acylase 85.8% 2004 172
PTMS-SBA 15 95.0 A Penicillin G acylase 97.2% 2004 172
VTES-SBA 15 102 A Penicillin G acylase  100% 2004 172
COOH-SBA 15 102 A Penicillin G acylase 84.2% 2004 172
21 SBA 15 Porcine Pancreatic Lipase (PPL)
(46  26  11 A)
Max: 926 Max: 414 U/g 2009 200
22 SBA 15 66 A Porcine Pancreatic Lipase (PPL) 177 36% 2010 201
Dimethyl-SBA 15 66 A Porcine Pancreatic Lipase (PPL) 178 43% 2010 201
Diisopropyl-SBA 15 66A Porcine Pancreatic Lipase (PPL) 193 72% 2010 201
Diisobutyl-SBA15 66 A Porcine Pancreatic Lipase (PPL) 208 61% 2010 201
23 Folded-sheet
mesoporous silica (FSM)
40–85 A
Alanine racemase fromGeobacillus
stearothermophilus
30–60 Retained 51% of the free enzyme
activity. Improved thermal stability
2010 202
a The adsorption was conducted at pH of 7.0 and the unit is ‘‘amount adsorbed/(mmol g1)’’. b The adsorption unit is ‘‘mg/100 mg FSM’’.
c Functionalised FDU-12 includes: amine, vinyl, thiol and phenyl (organosilanes). d The adsorption amount of vinyl-FDU.including protein, genes, DNA and large antibiotics fromMSNs;
many studies have highlighted these effects. Hata et al. first
reported the effect of pore size and influence of solvent on the
loading and release of the anti cancer drug Taxol in 1999.40
Further studies by Vallet-Regi and co-workers confirmed the role
of pore size as an important factor determining the adsorption
and release of biomolecules. There are other pieces of evidence
where pore size has effectively altered the loading and
release.13,38,41–44
Recently, intertest has turned to the synthesis of orderedMSNs
with ultra large pores (10–30 nm). A large pore size is advanta-
geous, especially in cases of protein and DNA adsorption due to
their size. Fan et al.were the first to create an orderedmesoporous
material with an ultra large pore size of around 30 nm.45 Qiu and
co-workers recently synthesised MSNs with ultra large pores
(20–40 nm) with interconnected channel structures. These parti-
cles have also shown good protein separation capability.46 In an
another finding,Botella et al. reportedmonodispersedMSNswith
20 nm pores using a dual surfactant system and lower synthesis
temperature. They observed enhanced adsorption of plasmid
DNA due to the large pores, and reported highest DNA content
achieved so far on silica based materials (0.07mg DNA m1).47
Proteins can interact with mesoporous materials through three
main interactions - physical adsorption, encapsulation and
chemical binding. Many different proteins have been successfully
adsorbed onto the surfaces of mesoprous silica materials. Pore
size is also a major factor affecting the loading of proteins into
the mesoporous silica network. Small pores result in most of the
proteins remaining on the surface and thus not utilising the large
internal surface area presented by the pores. It has been shown2806 | Nanoscale, 2011, 3, 2801–2818that large proteins can be easily and quickly adsorbed and
released on large pore silica materials such as MCFs.48,49
Furthermore, the pore size can provide additional advantages
including size selective separation of protein solutions. Katiyar
and Pinto were able to demonstrate this with SBA-15 materials
using two different proteins lysozyme and bovine serum albumin
(BSA). By using confocal scanning laser microscopy, they
showed that the smaller protein lysozyme was adsorbed into the
pores of SBA-15 and the larger BSA remained outside - not
inside - of the pores.50 Furthermore, this shows thatMSNs can be
used for protein separation. Qiao and co-workers combined
MCM-41 type MSNs with magnetic Fe3O4 to produce magnetic
silica nanospheres.133 Using the resulting magnetic nano-
composite as an adsorbent, they demonstrated the selective
separation of cytochrom C (Cyt C) from a bicomponent solution
of BSA and Cyt C with a magnetic field.51
As discussed previously, limitations in the pore size of silica
materials for in vivo delivery is a major hurdle for the loading of
large biomolecules, however, there have been some studies
showing that RNA and DNA can be successfully incorporated
into the silica materials52. These RNA/DNA segments or frag-
ments are generally small in size due to the small pore size of the
materials.53 However, it has been proven to be successful. An
excellent example of DNA adsorption and delivery was the work
by Torney and co-workers. They demonstrated that by using
silica materials as delivery vehicles, with a pore size of 3 nm, the
DNA adsorbedMSNs were easily taken up by the plant cell walls
and healthy leaves.54 Solberg and Landry reported that DNA
with 760 and 2000 base pairs in length were adsorbed into
various pore sizes of mesoporous silica.55This journal is ª The Royal Society of Chemistry 2011
Fig. 1 Schematic illustration of the formation of multi-shelled meso-
porous silica hollow nanospheres.342.2.3 Surface area. Surface area also has a significant impact
on the loading and release of cargo molecules in mesoporous
materials. It has been well understood that with an increase in
surface area, the number of active sites for adsorption increases,Fig. 2 Procedure for the preparation of yolk–shell structures with
a mesoporous shell (top image). Yolk–shell material synthesized using
silica spheres with 260 nm as core. a) SEM image, b) TEM image.29
This journal is ª The Royal Society of Chemistry 2011and therefore adsorption of the molecules increases. This has
been verified for alendronate for example, under the same
conditions.13 In an anther study, surface area had only little
impact on adsorption of Ibuprofen.56 Unfortunately, the volume
of literature citing this is not significant.
2.2.4 Surface chemistry and functionalisation of MSNs.
Surface functionalisation of MSNs is typically carried out using
the one-pot synthesis (co-condensation), post synthesis (graft-
ing), and PMOs (Periodic mesoporous organicsilica) synthesis
method. Researchers have observed that the degree of func-
tionalisation is dependent on concentration, molecular size and
the hydrophilic/hydrophobic nature of co-condensing agents.
Moreover, shape of the particle is also dependent on the type of
co-condensing agent used. For instance, a hydrophilic co-
condensing agent leads to the formation of small and round
particles while hydrophobic one gives rod shape particles.
However, one-pot-synthesis suffers from some disadvantages.
For example, the degree of structural orderedness decreases with
an increase in concentration of the co-condensing agent; a higher
concentration can also lead to decrease in pore diameter.57,58
An alternative method to attach the desired functional group
on to the surface of the silica is the post-synthesis grafting
method, whereby organic functionalities are added after removal
of surfactant. This method offers the advantage of selectivity,
whereby selectively coating of mesoporous silica matrix is more
controlled and optimum. However, it can also lead to a non-
homogenous surface coating. This is because the silanol groups
on the surface are more accessible than those inside the pore wall.
Surface functionalisation is one of the important factors in
controlling the adsorption and release of biomolecules. For
instance, surface functionalisation of MSNs with amine groups
shows the direct relationship between the release rate and the
amount of amino group. Many studies have been carried out to
achieve controlled and stimuli-responsive drug delivery systems
using functionalised MSNs.37,59–78 There are many reasons as to
why functionalisation is important, but it is mainly carried out to
increase the loading of the molecules and to improve the inter-
particle and molecular relationships such as increasing the
stability of the bond and improving biocompatibility. Other
examples include targeted and controlled drug release. For
example, the use of amino groups onto the surface of the
MSNs62,67,72,79,80 and alkyl chains increases the amount of drug
adsorption.63,81 This property has been utilised recently to
construct stimuli responsive drug delivery systems.61,65,69,75,82–86
One of the most promising reports for functionalisation of
MSNs is by Mal et al.,59 where they grafted coumerin onto the
outer surface of mesoporous silica using as-synthesisedMSNs, so
that they could achieve high adsorption selectivity and speci-
ficity. Upon UV light irradiation (at 310 nm), dimerisation of
coumarin closes the gates on the surface of silica. Subsequent
irradiation of light at 250 nm leads to the breakdown of the
coumarin dimer, hence releasing the loaded compound loaded
inside the pores.59
Many studies have shown that surface functionalisation
improves the adsorption capacity of the proteins by introducing
electrostatic bonding. Uses of amine groups, disulfide bonds or
with the introduction of thiols have significantly improved
adsorption capacity of many drugs (Table 1). Amino silicas areNanoscale, 2011, 3, 2801–2818 | 2807
one of the most widely used functional groups with regards to
protein binding and immobilisation. Many researchers have
shown that the amino functionalisation can give the material an
overall net positive charge, thus improving electrostatic bonding
with biomolecules. The functionalised materials then display
greatly enhanced bio-adsorption capacity compared to the
unfunctionalised or native counterparts.68,73,78,872.3 Other factors affecting the adsorption and release of
biomolecules in MSNs
One of the important factors influencing the amount of protein
adsorbed onto the surface of mesoporous silicas is the pH at
which the adsorption is carried out. Various studies using silica
materials as adsorbents have shown that the maximum adsorp-
tion of protein occurs at or near the isoelectric (pI) point of the
protein. For example, myoglobin, cytochrome c (cyt c) and
(BSA) have been shown to have a higher adsorption capacity
onto the materials at a pH equal or less than the pI point of the
protein.88–91 This is caused by the electrostatic interactions
between the protein and the MSNs. Because the repulsive forces
between the adsorbed protein on the surface of the material and
protein left in solution are minimal at its pI point.91
MSNs have been used to attach many polymeric structures to
achieve controlled and predicted release of cargo molecules.47,92
Rosenholme et al. recently coated mesoporous silica with poly-
ethylineimine (PEI) and it was further modified using a fluores-
cent component to track MSNs in cells. They showed that
functionalised MSNs were five times more internalised into
HeLa cells than to unfunctionalised particles. PEI functionalised
particles were stable, nontoxic, and further used to attach other
biomolecules such as folic acid and fluorescent dyes effectively.93
The literature cited above shows the versatility and effective-
ness of MSNs not only as a carrier for adsorption and release of
host molecules but also as a suitable means for achieving effective
surface chemistry. In contrast to this, a study on structural
activity relationship for MSN in drug delivery showed that
surface functionalisation did not always have an impact on
adsorption and release.94 They found the least influence of the
surface amino group on adsorption and release of salicylic acid
from the MSN support. Hence, it is necessary to take into
account other factors such as pore size, pore volume, surface area
and shape of MSN for the optimisation process. The above
studies on the factors affecting adsorption and release suggest
that pore size, surface area, shape and surface area, and surface
functionalisation all contribute to the adsorption in, and release
from, MSNs.
By creating a coating on the silica, it is also possible to increase
the loading of DNA on the surface ofMSNs, while having a drug
loaded inside of the pores. This can effectively increase the
biocompatibility of the material and can improve the uptake into
cells. For example, coating various molecular weights of PEI on
the surface of mesoporous materials can increase their adsorbed
amount of DNA and siRNA. This coating can then improve
the delivery of the drug Paclitaxel as the positive charge of the
polymer coating allows the particle to easily transfect inside the
cell.76 This PEI coating has also been shown to be effective in
the delivery of the siRNA into mammalian cells.2808 | Nanoscale, 2011, 3, 2801–2818The particles were taken up into the lysosome of the cells
where siRNAwas released. Plasmid DNAwas also loaded on the
PEI coated MSNs and effectively delivered into cells.96 Meso-
porous silica nanoparticles have been used as dual drug delivery
carriers, where drug molecules can be adsorbed in mesopores and
SiRNA conjugated on the surface. It showed improved uptake
and reduced cytotoxicity (Fig. 3).95
As many new vaccines use only fragments of the virus
compared to the whole antigen, mesoporous silica can be useful
in the protection and delivery of antigens to targeted cells. There
have been a few studies showing that the mesoporous silica acts
as good adjuvants, resulting in an increase in the efficacy of the
vaccine. Mercuri and co-workers demonstrated that SBA-15
loaded with a 16.5 kDa recombinant protein Int1b from E.coli
can protect mice from the venom of snake species Micrurus.
Compared with conventional adjuvants, it was shown that the
antibody response was much higher than what was currently
available.97 Composite materials such a poly(d,l-lactide-co-gly-
colide) (PLGA) coated MCM-41 was also shown to be effective
in the use of prime boost vaccinations.983. Cytotoxicity of MSNs
Due to the varied structure of mesoporous materials and the
different synthesis methods, examining biocompatibility is
a challenge as it is often difficult to create similar physiological
conditions both in vitro and in vivo.37 At relatively low doses,
silica nanoparticles are non-toxic but become toxic at higher
doses as they induce cell damage.99 Early cytotoxicity tests
showed that compared to solid silica spheres, MCM-41 was
found to be less toxic.100Recently, many studies have focussed on
the cytotoxicity of mesoporous silicas, many of which concluded
that the type of surface functionalisation can have a drastic effect
on the toxicity of the material.101,102 In vitro studies have shown
extensively how mesoporous silica interacts with various cell
lines. Some of these include 3T3 endothelial cells,103 human colon
carcinoma (Caco-2),104 glioma cells101 human mesenchymal stem
cells105 and HeLa cells.106–108
Several articles reported the influence of size dependent cyto-
toxicity. In human monocyte-derived dendritic cells, there exists
a size effect where larger micron sized silica particles (2.5 mm) are
more toxic than smaller sub micron (270 nm) sized mesoporous
silica with higher dosages being more toxic than lower dosages.109
This size effect can also be observed where human endothelial
cells are used with amorphous silica particles. Silica below 20 nm
was much more toxic than silica particles that were 104 and 335
nm in size. These larger particles showed very little toxic
effects.110Having particles in the sub-micron range below 500 nm
is desirable as they are easily taken up by the cell through
endocytosis and can be seen localised in the lysosomes of the
cell.111
Dosage is also an important factor, which needs to be deter-
mined. Researchers have shown that there is a dosage effect as
MSNs are relatively non-toxic in low concentrations. In a study
on COS-7 and MDA-MB-468 cells, it was found that at low
concentrations below 25 mg mL1, there was very little toxicity.
Above this level, the particles started showing some toxic
effects.112This journal is ª The Royal Society of Chemistry 2011
Fig. 3 Schematic and uptake mechanism of drug loaded and siRNA coated mesoporous silica.95The synthesis method used can also play some part in the
toxicity as demonstrated by He and co-workers when they tested
differentMCM-41 type particles synthesised using CTAB, Triton
and SDBS on MCF-7 cells. They found that the order of toxicity
was CTAB > SDBS > Triton. However, CTABMSNs performed
the best when it came to efficacy.113 Furthermore, the effect of the
shape of the particle appears to have little effect on the toxicity in
A375 melanoma cells using spherical MSNs (100 nm diameter),
short rods (240 nm length) and long rods (480 nm length).114
The effect of mesoporous silica materials on hemolytic activity
is important in order to understand how the materials will
interact with blood. In a study by Lin and Haynes, they found
that there were significant effects of size, porosity and dosage on
the activity of the hemolytic cells. They reported that MSNs with
ordered structures reduce the activity of these cells compared
with the solid nonporous particles of similar size due to
a reduction in the amount of silianol groups on the surface.
However, this could be overcome with the addition of poly-
ethylene glycol (PEG) coatings, which were also able to increase
the activity.115 Hemolytic assays have recently been tested with
hollow mesoporous silica. Again, at low dosages (up to 1600mg
ml1) these hollow mesoporous silica showed no effect on the
activity of the cells.116 He et al. obtained similar results that
PEGylated MSNs greatly influenced the non specific serum
binding and had showed significantly reduced haemolysis rate
compared to non PEGylated MSNs.117
In vivo testing of the MSN particles has been so far limited to
small rodents such as mice and rats. Hudson and co-workers
tested the biocompatibility of three main types of silica nano-
particles MCM-41, SBA-15 and MCF. They used several
different sites of injection such as intravenous, intraperitoneal
and subcutaneous. The systemic biocompatibility of such
nanoparticles was questioned as mice injected intravenously had
rapid deaths and some deaths were also caused from the
intrperotoneal injection. Subcutaneous injections were relativelyThis journal is ª The Royal Society of Chemistry 2011safe as none of the animals died.118 However, the dose rates were
quite high being 0.17g kg1 for rats and 1.2g kg1 for mice and the
MSN nanoparticles were not functionalised. At a dosage of
MSNs at 40mg kg1 into the tail base, PEI coated MSNs had no
apparent toxic effects on the mice. This difference between the
in vivo and in vitro tests is due to different types of cells which are
present in the body. Instead of testing on one type of cell, the
body has several defence mechanisms, which are able to combat
the entry of foreign objects.76 The biodegradability of silica
particles has been shown in mice with the use of fluorescent
labelled silica particles. Again the dose rate was kept low at
20 mg kg1 and the particles were cleared from the body through
the renal system.119
Although there have been several studies on in vivo behaviour
of MSNs, none of the studies has explained the distribution and
elimination of MSNs in different organs. Recently, Souris et al.
showed hepatobiliary excretion of MSNs.120 They used positively
charged MSNs with different charge densities for their studies.
Using in vivo and ex vivo fluorescence imaging and inductively
coupled plasma-mass spectroscopy, they explained the elimina-
tion behaviour of MSNs from liver. They prepared two different
types of positively chargedMSNs, MSN-NH2-ICG(Indocyanine
green) with zeta potential of +34.4 mV at physiological pH 7.4
and MSN-TA-ICG with a zeta potential of 17.6mV. Their
results showed that MSN-NH2-ICG underwent rapid uptake
and elimination via liver while MSN-TA-ICG possessed high
uptake and retention in liver. It is interesting to note that charge
type and density can be used as a technique to control the resi-
dence time of nanoparticles inside the body.120
4. Stimuli responsive MSNs for adsorption,
controlled and targeted delivery
Traditional delivery systems based on polymers and other types
of inorganic materials do not exhibit stimuli responsiveness.Nanoscale, 2011, 3, 2801–2818 | 2809
Especially with polymeric systems, there is always a danger of
premature release of cargo molecules before reaching the site of
action. Many stimuli responsive systems attempted to overcome
the disadvantages of established systems using MSNs as carriers
for targeting cells. These systems are mainly activated by chem-
ical triggers such as pH, enzyme, functional groups, temperature
or photons to achieve the desired controlled and predictable
release of biomolecules (Table 1) at the desired site.4.1. pH responsive system
pH is one of the most widely used biological commands to trigger
drug release since the pH within the body and biological cells has
been well known and it is easy to target a particular organ on the
basis of pH. In the last few years, many pH responsive systems
based on MSNs have been developed to release various types of
molecules like drugs, dyes and other chemical moieties.84,121–125
Cyclodextrin and PEI complexes were utilised by Kim and co-
workers to achieve release in an acidic environment. Guest
molecules were first loaded into pores and then Cyclodextrin
(CD)/PEI inclusion complexes were attached onto the surface of
MSNs. Due to the bulkiness of these compounds the cargo is
protected until polypseudorotaxane is ruptured. Under acidic
conditions, the CD complex can be broken and hence release of
cargo.74 Zink and co-workers recently reported a promising pH
operated, mechanised, nanoparticles-based system with precise
control over the release into the lysozyme and cells where the
environment was acidic. They modified amino-functionalised
MSNs with a pumpkin-shaped cucurbituril forming a pH
dependent complex with the silica. At lower pH levels, clock like
mechanised particles opened up and released propidium iodide
(PI); the clock closed at higher pH levels.84
In another example, Zink and co-workers showed that
a similar type of release action could be achieved using cyclo-
dextrin derivatives as pH responsive linkers (Fig. 4).126 pH based
delivery of Vitamin B2 was also achieved using amino func-
tionalised nanoscopic gates62Much effort is devoted to pH based
systems that releases cargo in an acidic environment due to its
applicability into lysozymes and cancerous cells where pH is
mildly acidic. However, these systems can also be utilised for
conventional drug delivery where neutral pH is equally impor-
tant to deliver drugs into the intestine. There are very few
examples showing release at neutral pH. Kawi and co-workers
made polyacrylic acid coated MSNs to achieve the release of
protein at physiological pH.123 Hence, research based on MSN
lacks conventional targets such as the colon, small intestine, and
liver. It will be interesting to see the effect of these novel nano-
particles upon these human organs.4.2. Enzyme responsive systems
Zink and co-workers developed a dual snap-top system specific
to liver esterases, which released the cargo upon addition of the
enzyme (Fig. 5). Other examples such as bitin-avidin capped
MSNs as a protease responsive and lactose coated MSNs based
enzyme responsive system make these systems versatile as it can
be utilised for many enzymes.60,122,139 In addtion to this, Park
et al. prepared alpha-amylase and lipase responsive MSNs using
b-CD capping.1442810 | Nanoscale, 2011, 3, 2801–2818Very recently, Chen et al.145 prepared temperature and enzyme
responsive MSN based scaffolds. These nanovalves can respond
to both external stimuli, temperature and internal stimuli such as
deoxyribonuclease I, an enzyme making them ideal for cellular
delivery. Anticancer drugs such as camptothecin and floxuridine
were successfully loaded and released with the above-mentioned
triggers. Above examples showed the capability of these systems
for drug and gene delivery. To date there are only a few examples
of enzyme-responsive systems based on MSNs. Moreover, there
are no reports of performance of these systems in vivo or ex-vivo.4.3. Chemical trigger responsive systems
Lin and co-workers reported many systems with zero premature
release of biomolecules based on the MCM-41 type of
MSNs.54,61,82,86,128,134,146,147 A classical example of their work was
MSNs capped with CdS nanoparticles to achieve release upon
amidation. They showed that coated CdS nanoparticles acted as
a gate-keeper for the release of biomolecules. An antibiotic
Vancomycin was successfully loaded and released depending on
the degree of cleavage of the disulfide bond.61 Recently, they
reported a magnetic nanoparticles coated MSNs (nanorods)
system with zero premature release (Fig. 6). Instead of CdS
nanoparticles they used supraparamagnetic iron oxide nano-
particle as a coating material showing that release was induced
by anti-oxidants.147
A recent example of a stimuli responsive mesoporous silica-
based delivery system is the glucose responsive delivery of
insulin. As shown in Fig. 7, gluconic acid modified insulin
proteins (G-ins) were immobilised onto the exterior surface of
aminopropyl functionalised mesoporous silica.
Saccharides, for example glucose, can trigger the release of
protein, which can then release the cyclic adenosine mono
phosphate (AMP) in cells. cAMP then activates the Ca2+ chan-
nels in beta cells of the pancreas and hence releases insulin.
Results demonstrated good in vitro and ex vivo insulin release.82
This system can potentially be used for diabetic patients who are
suffering from cellular problems related to insulin release.4.4. Thermal responsive systems
Temperature sensitive polymers are used in many drug delivery
systems due to their unique properties such as their ability to
swell above certain temperatures and shrink below certain
temperatures. Such systems can be useful in biological systems to
achieve stimuli responsiveness if necessary. Poly-N-iso-
proplyacrylamide (PNIPAm) (which can be used for delivery of
biomolecules) is well known for its temperature responsive
properties and was coated on double bond functionalised silica
microspheres by radical co-polymerisation.148 Recently, Chung
et al. prepared similar composite particles using aromatic func-
tional groups grafted onto the surface of MSN followed by
RAFT (Reverse Addition – Fragmentation Chain Transfer
Reaction). More importantly they found that the temperature
responsive conformation changes in PNIAm can bring about
changes to the silica structure. This strategy can be utilised to
prepare stimuli responsive MSN based nanovalves, where drugs
can be loaded inside the porous structure and released at
a certain temperature.149 Using the novel W/O pickeringThis journal is ª The Royal Society of Chemistry 2011
Fig. 4 Design of pH dependent systems based onMSNs by changing the
value of R; pH response can be fine tuned and release of propidium iodide
can be controlled84,126
Fig. 5 Enzyme responsive snap-top system based on MSNs.60
Fig. 6 Schematic of the stimuli-responsive delivery system (magnet-
MSNs) based on mesoporous silica nanorods capped with super-
paramagnetic iron oxide nanoparticle.147emulsion based technique and solid silica sphere as a stabiliser,
Zhang et al. prepared temperature responsive hybrid capsules
made up of PNIPAm and polymethyl methacrylates (PMMA).
Ibuprofen release from the composite particles was controlled by
temperature and wall thickness of the polymer.150 An interesting
system is recently designed to contain zinc-doped iron oxide
nanoparticles within mesoporous silica network and pesudo-
taxanes. Upon AC magnetic field local internal heat (thermal
energy) opens the molecular gates to deliver drugs.1514.5. Polymer coated MSNs
Recently, many studies have examined the coating of MSNs with
a polymer because of its broad applicability in drug delivery,This journal is ª The Royal Society of Chemistry 2011gene delivery and other biomedical applications. Coating of silica
based inorganic nanoparticles with biodegradable polymers such
as polymethyl methacrylates (PMM), polystyrene and polylactic
acid (PLA) have been extensively studied.47,92,152 Such a coating
offers many advantages over uncoated nanoparticles like
controlled and sustained release, stimuli responsiveness towards
pH, enzyme and photon or light.124,152,153
Many methods have been developed in the past to coat
a polymer onto a mesoporous support including free radical
polymerisation, reversible addition-fragmentation chain transfer
(RAFT), emulsion polymerisation, and solid-oil-in water emul-
sification (S/O/W).92,124,127,152,153
Shi et al. developed hydroxyapatite (HA) polylactic-co-gly-
colic acid (PLGA) coated composite microparticles for
controlled release of biophosphonate additives based on a S/O/W
method. They showed that coating mesoporous silica with
barrier layers such as a polymer can effectively reduce the burstNanoscale, 2011, 3, 2801–2818 | 2811
Fig. 7 Glucose responsive MSN based delivery of Insulin.82
Fig. 8 Sustained release of aldreonate from composite microparticles.85
Fig. 9 Novel synthesis strategy to coat PMV onto Mesoporous silica.124release of a drug or biomolecules from uncoated nanoparticles
(Fig. 8). Interestingly, coated particles were less cytotoxic than
uncoated particles and showed sustained release of aldreonate
over one month.85 It was an interesting approach to coat a layer
of HA first onto mesoporous silica to protect biomolecules and
then coat PLGA using the S W1/O emulsification method as it
showed a decrease in the burst release.85
Huang et al. carried out a similar study where they used the
same method (S/O/W) to coat PLGA onto magnetic mesoporous
silica spheres. The composite particles were severalmicrons in size
and showed an effective decrease in burst release of Ibuprofen
under simulated conditions.141 One of the disadvantages of this
method is that the effect of various formulation variables on the
size, shape and release of drugs is poorly understood. Particle
sizes of composite microparticles are around 100mm, which
makes this system less useful for cellular delivery and specific drug
target delivery. To overcome this problem, Gao et al. reported
a novel method to effectively coat several layers of a polymer to
get a pH responsive release of Ibuprofen. Poly-methylacrylic
acid-co-vinyl triethoxylsilane (PMV) was successfully coated
ontomesoporous silica by the free radical polymerisationmethod
(Fig. 9). Their results suggested that the polymer was coated onto
mesoporous silica without altering the particle size too much.
These composite nanoparticles showed the pH responsive release
of Ibuprofen.124 Recently, Ho et al. prepared PLGA coated
compositemicroparticles using a novel dual concentric ultra sonic
atomisationmethod for DNAprime boost vaccination. Themain
advantage of this method is that it produces smaller size particles.
Results showed that using this novel technique, particles of up to
6mm can be formed. This cannot be utilised for cellular drug
delivery due to its size. However, this is the first report of small
composite MSN-PLGA microparticles. Moreover, they showed
a remarkable loading efficiency of up to 98%. Particles were
uniform in particle size and morphology and showed almost zero
release for long periods of time. However, this technique is not
reproducible and it is hard to control certain factors such as
particle size and wall thickness during scale up.1542812 | Nanoscale, 2011, 3, 2801–2818Free radical polymerisation, reversible addition-fragmenta-
tion chain transfers (RAFT), and emulsion polymerisation can
be utilised to form various target specific and cell specific delivery
systems using MSNs. However, as evident from Fig. 9, the drug
was loaded after the polymer was coated onto the mesoporous
silica, which led to poor drug loading into mesopores compared
to methods like S/O/W. In more recent methods, the drug is
loaded into the mesopores prior to polymer coating, and the
polymer is coated onto them. The latter suffers from water
soluble molecules leaking into the continuous phase, leading to
poor drug loading. Hence, there is a need to develop a system
that can offer the dual advantage of higher loading efficiency and
effective functional coating for targeting.5. Enzyme immobilisation
Enzymatic bioprocesses have the major advantages of high
selectivity and yield compared to chemical synthesis routes. These
processes have beenwidely used inmany industries, for example in
the production of ammonium acrylate, and the removal of heavy
metals from wastewater.155,156 They are also applied in the
synthesis of fructose from starch in the food industry157 and
production of 6-aminopenicillanic acid (APA) in the pharma-
ceutical industry.158 The main obstacle for these processes to be
industrially feasible is the high cost of enzyme production.155This journal is ª The Royal Society of Chemistry 2011
An unbound (free) enzyme usually has low stability towards
heat, organic solvents, acids or bases and its recovery is difficult.
In addition, the expense of producing this makes it less an option
as an industrial catalyst compared to other chemical catalysts.
Futhermore, enzymes have highly controlled regio-, stereo- and
substrate-specificity. The enzymatic reactions generally proceed
under very mild conditions. It is thus highly desirable to improve
enzyme stability and reusability. Ultimately, this will help reduce
enzyme production costs.70,159 Techniques to improve enzyme
stability include enzyme immobilisation, enzyme modification,
protein engineering and medium engineering. Enzyme immobi-
lisation can attach an enzyme on the surface or inside the pore of
a solid carrier.159,160,161
Enzyme immobilisation can be conducted through physical or
chemical adsorption onto solid supports and via physical
entrapment or encapsulation within a polymer network.155,162–164
Adsorption is a simple and inexpensive method however enzyme
leakage is a problem. Entrapment or encapsulation is a good way
to prevent direct contacts between enzymes and a harsh envi-
ronment; however these methods have drawbacks of mass
transfer limitation and low enzyme loading.163
A wide range of enzymes have been immobilised onto various
mesoporous silica materials (Table 2). This section will summa-
rise the studies of enzyme immobilisation onto mesoporous silica
materials.5.1 Mesoporous silica materials as supporting agents for
enzyme immobilisation
Balkus et al. reported lysozyme immobilisation within MCM-41
matrices. This study highlighted the importance of silica pore size
to encapsulate the enzyme. But, MCM-41 could not encapsulate
a biomolecule with a size greater than 40 kDa.165,166 On the other
hand, SBA-15 with larger pore sizes (5–30 nm)167 opened wider
possibilities to encapsulate various larger proteins. However,
SBA-15 materials (pore sizes 6.8 nm) showed a small adsorption
amount of larger protein such as bovine serum albumin.168
Sun et al. was able to perform highly accelerated lysozymes
adsorption by enlarging the conventional SBA-15 pore. They
created ordered large mesopores with a pore size of 13 nm.
Adsorption of enzymes reached equilibrium after 10 min as
compared to hours for the conventional SBA-15. They could also
confirm that most of the lysozymes were within the pores.169 Liu
et al. reported the fabrication of silica hollow spheres with highly
ordered hexagonal arrangement of the mesopore in the shell via
a simple O/W (2,2,4-trimethylpentane (TMP)/water) emulsion
template method in the presence of (EO)20(PO)70(EO)20 under
buffer solution (NaAc-HAc, pH ¼ 4.4) using tetramethoxysilane
(TMOS) as a silica source. The mesoporous silicas exhibited
a high adsorption capacity (up to 536 mg g1) and very rapid
(<5 min to reach equilibrium) lysozyme immobilisation. More
importantly, it was revealed that mesoporous silica hollow
spheres with rugged surfaces can greatly accelerate the enzyme
adsorption rate during the adsorption process.170
Fan et al. successfully synthesised ordered large pore cubic
mesoporous silica (FDU-12) with pore sizes up to 27 nm. This
cubic structure displayed better performance compared to the
2-D structure (MCM-41, SBA-15) in terms of pore blockage.45,171
The main advantage of larger pore sizes is the efficient massThis journal is ª The Royal Society of Chemistry 2011transfer of the guest molecules within the porous network. FDU-
12 mesoporous silica materials certainly offer wider applications
for bio-molecule encapsulation. We recently synthesised ordered
functionalised cubic FDU-12 mesoporous silica with a cavity size
of 25.4 nm and entrance size of 10.5 nm (Fig. 10). These silicas
have been used to study the immobilisation of large cellulase
enzymes. We found that around 50% of the enzymes were
successfully loaded into the pore.112
Enzyme immobilisation must focus on achieving high enzyme
stability. The stability can be divided into operational stability
and storage stability. Operational stability indicates the capability
of the enzymes to maintain their activity, while storage stability is
related to the performance of the immobilised system in avoiding
enzyme release. The main concern of enzyme immobilisation is
loss of enzyme activity over time. The reduction is caused bymany
factors: pore diffusion resistance, low substrate mass transfer,
paralysed enzyme active sites and limited enzyme mobility.172,1735.2 Enzyme activity on mesoporous silica materials
Improving the geometrical structure of silica supports through
pore enlargement is one of the popular methods to minimise
diffusion resistance. Pore size affects not only the extent of
enzyme immobilisation but also enzymatic activity. Lu et al.
confirmed that when comparing pore size, pore volume, meso-
phase and surface area of the mesoporous materials, pore size
had a greater effect on immobilised enzyme activity.174 Addi-
tionally, it is necessary to strengthen the bonding between the
enzymes and the supports. Introducing functional groups into
supporting material surface can improve enzyme-support inter-
actions and reduce leakage of immobilised enzymes.70
Interestingly, Lei et al. showed from their research that
immobilised enzymes within the functionalised mesoporous silica
had a doubled activity compared to free enzymes.175 Chong et al.
proved that the activity of immobilised penicillin G acylase
(PGA) within vinyl-functionalised mesoporous silica support
was higher than free PGA.172 These results indicated that
immobilised enzymes can perform better when enzymes were
immobilised in the right supporting materials.
Park et al. reported lysosyme immobilisation within different
supports: SBA-15 and PMOs. They made three different PMOs
by using three different precursors: BTMS-amine, BTES-
benzene and BTES-phenyl. This study confirmed the significant
influence of a solution’s pH in protein adsorption. At pH near
the pI, because of hydrophobic surface, silica can reach an
optimum loading amount.119 At this pH, the electrostatic
repulsion effect among the proteins was minimised and thus the
protein can be arranged in a more compact construction.
One of the prominent properties of mesoporous silica is the
abundant silanol groups on their surface. These silanol groups
are highly reactive and hence can be used to attach several
functional groups on the surface of silica. The surface modifi-
cation increases the affinity between enzymes and supporting
materials. It has been found that retention of immobilised
enzyme activity is strongly influenced by surface chemistry of the
supporting materials.176
Chong et al. studied immobilisation of penicillin G acylase
(PGA) into functionalised SBA-15 like mesoporous silica mate-
rials. Different organosilanes were used for functionalisation:Nanoscale, 2011, 3, 2801–2818 | 2813
Fig. 10 High resolution of TEM and SEM images of very large pore
Amine functionalised FDU-12 materials.112
Fig. 11 The ‘Fish in Net’ method to encapsulate enzymes within the
silica network.1783-aminopropyltriethoxysilane (APTES), 3-mercaptopropy-
ltrimethoxysilane (MPTMS), phenyltri-methoxysilane (PTMS),
vinyltriethoxysilane (VTES) and 4-(triethodysilyl)butyronitrile
(TSBN). Further, they modified APTES-SBA-15 with a cross-
linking agent called gluteraldehyde. Most of the functionalised
samples had a higher PGA adsorption amount compared to non-
functionalised silica. They found that vinyl group functionalised
silica was very effective functionally for adsorption and stability
of PGA.
Vinyl functionalised silica enabled the enzyme to maintain
a stable conformation structure and a flexible mobility of the
active sites. As a result, the immobilised enzymes maintained
a high activity.172 Many researchers have used gluteraldehyde to
crosslink aminopropyl functionalisedMSNs to immobilise PGA.
Results showed that the covalent bond interactions could
improve the stability of immobilised PGA.172,177
In contrast, some researchers believed that enzyme immobili-
sation through covalent bonding using a cross linking agent such
as glutaraldehyde may cause a reduction in immobilised enzyme
activity. The bonding could cause a conformational change of
enzymes, which affects enzyme’s flexibility and mobility to
convert the substrate.179,180 In this case, it was preferable to use
non-covalent bonding, such as physical adsorption, electrostatic
interactions, hydrophobic interactions, etc. PGA has been also
immobilised on the APTES functionalised SBA-15.181 Interest-
ingly, the mesoscopic order of the SBA-15 can be maintained
even after the immobilisation of PGA. The author used a graft-
ing method for amine functionalisation of SBA-15 as the co-
condensation method resulted in disordered structure.69 The
loading amount of the PGA was 68 mg g1 of amine-function-
alised SBA-15. It can maintain 73% activity of its free form.181
Our recent study showed the importance of organic func-
tionalisation (amine, vinyl, thiol and phenyl) of a silica2814 | Nanoscale, 2011, 3, 2801–2818supporting material for enzyme immobilisation and activity
maintenance.177 The functionalisation affected the protein (BSA
and cellulase enzymes) adsorbed amount and enzyme activity.
Vinyl functionalised silica (S-VTMS) had a promising result,
which demonstrated a high performance in enzyme immobilisa-
tion and enzyme activity as well as enzyme stability. Vinyl
organosilane introduced hydrophobicity to the silica surface,
which increased the silica surface’s affinity against the proteins
(BSA and cellulase enzyme). The vinyl mesoporous silicas were
able to maintain the enzyme activity. In contrast, amine func-
tionalised mesoporous silica (APTES) showed the highest
adsorption amount yet with low activity of immobilised cellulase.
The amine functionalisation induced electrostatic interactions
between the amine terminal groups of mesoporous silica and
carboxylic acids from the enzyme’s active sites. As a result, the
immobilised cellulase had a low activity182
The aforementioned methods to attach or immobilise enzymes
on the surface of silica face a challenge of enzyme release in
biological conditions. The leaking of immobilised enzymes
depends on the bonding strength between the enzymes and the
silica. Yang et al. used a different approach to immobilise
enzymes (fumarase, trypsin, lipase and PLE) using the one pot
synthesis method. In this process, enzymes were encapsulated
during synthesis of ordered mesoporous silica (‘fish in net’)
(Fig. 11), thus the enzymes were entrapped within the macro-
porous cage that was formed during the synthesis.178 The authors
claimed that all of the immobilised enzymes had high activity and
stability and this method might be applied to other types of
enzymes. Yet one must be cautious with the effects of silica
synthesis condition (pH, chemical substances, etc), which might
also affect enzyme activity. Due to small pore entrances of the
larger pored MSNs, they are more susceptible to blockages.
Therefore, the enlarged pore entrance would result in an increaseThis journal is ª The Royal Society of Chemistry 2011
in loading and mass transfer. The latest report from the Magner
group showed the utilisation of the unique metal-enzyme inter-
action for enzyme immobilisation.183 This group immobilised
His6-tagged protein onto nickel(II)-cyclam grafted SBA-15
mesoporous silica. They showed that the protein and the support
interacted through nickel coordination. This was a result of
interactions between the Ni2+ and the imidazole rings of the His6-
tag. No desorption was found from their leaching study.
Previous reports showed that this type of interaction had
advantages of high stability, high enzymatic activity and reus-
ability.12,184–186 Another distinctive approach for enzyme immo-
bilisation used surface-based click chemistry route.187,188 Bein
et al. studied the immobilisation of trypsin within mesoporous
SBA 15 material using the ‘click reaction’. Azide functionalised
SBA-15 reacted with acetylene modified trypsin in a copper(I)
catalysed Huisgen reaction. Furior Transformed Infrared Spec-
troscopy (FTIR), nitrogen sorption and Thermogravimetric
Analysis (TGA) confirmed the trypsin immobilisation. The
resulted immobilised trypsin showed retention of enzyme activity
and stability. No desorption was found under the experimental
conditions.756. Conclusion & outlook
In the past decade, there has been an intense focus on meso-
porous silica nanoparticle based systems with an accurately
predictable delivery. Many systems have been designed to target
cancer cells with some very promising results. However, only
limited reports focus on the actual formulation parameters such
as dosage forms, route of administration, stability, and storage of
final formulation using MSNs in a biological system.203 Despite
promising demonstration of MSN as drug delivery carriers, there
are some critical issues that need to be addressed to effectively
utilise MSN in biomedicine. Additionally, physiological inter-
actions between MSN and biointerfaces (enzyme, cells, recep-
tors, blood brain barrier etc) need careful attention. Detailed
understanding of surface functional groups and its effects in vivo
is a critical component in this process.
Recently, He et al. showed that MCM-41 can be completely
degraded in 15 days in 0.5 ppm SBF solution at physiological
conditions.204 They revealed for the first time the three-stage
degradation behaviour of MSNs and showed that it was greatly
dependent on the initial concentration and specific surface area
of MCM-41. Moreover, a recent finding showed that MSNs
based tablet dosage form showed some forms of dissolution in
simulated gestric fluid (SGF), which has not been shown
before.205 These recent findings suggest that the release from the
unfunctionalised MSNs is not only dependent on diffusion of
drugs from the mesopores, but also on dissolution of silica
nanoparticles. Hence, the development of in vivo biodegrada-
tion and biodistribution models would be highly required in
order to completely understand the bio-behaviour of these
nanoparticles.
Using MSNs as a diluent and filler was identified when Xu
et al. first reported the use of SBA-15 to make tablets. This
opened up a whole new area of application with these types of
materials.206 Tablets and capsules are one of the most widely used
dosage forms to deliver therapeutics to the human body. It will
be interesting to see the role of mesoporous silica for selectivelyThis journal is ª The Royal Society of Chemistry 2011targeting body organs such as stomach, small intestine, colon,
rectum, and brain using these conventional delivery systems.
As shown in the previous sections, many bioapplications exist
for mesoporous silicas. Many of these applications involve the
use of mesoporous silica material as a control delivery vehicle of
different biomolecules and how they are actively taken up in the
body. However, there is a limitation such as the pore size, which
results in the size of chemical moiety being restricted to a certain
size range. For delivery into cells, it has been shown that the
particles need to be small so that there is effective cellular uptake.
Large particles cannot be used for these types of application. In
contrast, these large pore particles can be used for enzymatic
processes to entrap and reuse the enzymes thus reducing the cost.
Future research related to material synthesis will be very much
directed towards preparation and evaluation of highly ordered,
small size and large pore MSNs. The extra large pore size (20–50
nm) will facilitate immobilisation of a broader range of enzymes
and increase the application of these materials in various areas
including bioanalysis, biotechnology, bioprocessing, food and
environmental systems.
For applications such as the delivery of drugs, vaccines, RNA
and DNA, conclusive cytotoxicity tests need to be performed for
each application and cell line. Currently there are many con-
flicting reports but there is a general consensus that MSNs are
relatively safe for delivery at low dosages and particle size
ranging 50–400 nm can ensure maximum uptake from the cells.
Long-term cytotoxicity tests also need to be performed to ensure
their clinical safety. Further studies in degradation, how the silica
is excreted or broken down in the body, also need to be exam-
ined. However, once this has been done, MSNs do appear to be
excellent candidates for bioapplications.
Another great property of MSNs is the use of silica as
a coating for smaller particles such as magnetic particles and
quantum dots (QDs). On their own, magnetic particles and QDs
are toxic, but coating with a silica layer makes them more
biocompatible. The resulting composite particles are thus excel-
lent candidates for in vivo imaging such as magnetic resonance
imaging. The ease at which the surface of MSNs can be func-
tionalised allows for an abundant array of new novel applica-
tions in a variety of fields. The challenging goal is to track these
nanoparticles not only to site of action but throughout its bio-
distribution and excretion. This will ensure the long term safety
of these nanoparticles in the human body.
A new family of magnetic mesoporous silica has also been
exploited for enzyme immobilisation, which shows promising
results. However, enzyme immobilisation must focus on
achieving high enzyme stability. It is expected that immobilised
enzymes have a high enzyme activity and minimum enzyme
desorption (leaching). However, literature citing this is unfortu-
nately very limited and further studies on this area are highly
desired.
Due to its unique characteristics, MSNs can also be useful in
other industries, for example agrochemical, where it can be used
for pesticide storage and delivery in a predictable manner. MSN
based encapasulation and delivery of pesticides could have some
positive environmental implications as well as decreasing the
extermination of non-target insects. The latest developments in
mesoporous silica synthesis have produced various materials
with very large pores and unique morphology. Lastly, the questNanoscale, 2011, 3, 2801–2818 | 2815
for intelligent nanomedicine based upon MSNs and its detailed
in vitro and in-vivo testing is one of the most important areas of
research in recent times and will be in near future.
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